CLOs on the Move

HemoShear Therapeutics

www.hemoshear.com

 
We are dedicated to discovering novel biological targets and developing drugs that profoundly improve the lives of people born with rare metabolic defects who are unable to sustain basic biochemical processes necessary for life.
  • Number of Employees: 25-100
  • Annual Revenue: $0-1 Million
  • www.hemoshear.com
  • 501 Locust Ave Suite 301
    Charlottesville, VA USA 22902
  • Phone: N/A

Executives

Name Title Contact Details

Similar Companies

Pear Therapeutics

Pear Therapeutics is a privately held prescription digital therapeutics company developing clinically validated, FDA-authorized software applications to treat serious medical conditions and is the leader in FDA-authorized prescription digital therapeutics.

Pennsylvania Environmental

Pennsylvania Environmental is a Philadelphia, PA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Bruker

Bruker is a Goleta, CA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Tyme

TYME, Inc. is a pharmaceutical company focused on creating medicines that specialize in using the body’s immune system to treat diseases. The body has the ability to fight off major diseases and heal itself. Tyme is researching a mechanism that it believes may work alongside the body’s immune system to fight Stage IV Metastatic Cancer. Tyme hopes to provide a novel compound for physicians to use in a treatment regimen for patients fighting six major cancers (breast, lung, prostrate, gastric, esophageal and pancreatic cancers) responsible for 62% of the annual cancer deaths in the United States. The SM-88, Tyme’s proprietary compound, is a novel compound that has the potential to alter defenses to oxidative stress and increase free radical availability to the cancer cell. SM-88 is designed to penetrate the living cancer cells and introduce multiple mechanisms to kill the cell. Inducing transfer of electrons in the cancer cells may allow catalyzed external free radicals to react and stress the cell. SM-88 is a combination of low dose agents used for non-cancer treatment.

RayzeBio

RayzeBio is a biotechnology company focused on improving outcomes for people with cancer by harnessing the power of targeted radioisotopes. With a focus on clinically validated solid tumor targets, RayzeBio is developing novel drug conjugates to deliver potent therapeutic radioisotopes such as Actinium-225, an alpha-emitter. The company is backed by a syndicate of sophisticated healthcare investors and was established in 2020